Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir

Digestive Diseases and Sciences

Volumn 60, Issue 11, 2015, Pages 3465-3472

  Fong, Tse Ling ^a,b   Tien, Andy ^a   Jo, Kahee J ^c   Chu, Danny ^d   Cheung, Eddie ^e,f   Mena, Edward A ^g   Phan, Quang Quoc ^h   Yu, Andy S ⁱ   Mohammed, Wafa ^a   Velasco, Andrew ^a   LeDuc, Vinh Huy ^a   Nguyen, Nickolas ^a   Han, Steven Bui ^j   Chang, Mimi ^a   Bae, Ho S ^a   Cho, Yong Won ^a   Tong, Myron J ^g   Cooper, Stewart L ^c  

^a ST VINCENT MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d PRIVATE PRACTICE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Private Practice   (United States)

^g Huntington Medial Research Institutes   (United States)

^h Private Practice   (United States)

ⁱ Private Practice   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Relapse; Remission; Seroreversion

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; TENOFOVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; GUANINE; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS B; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOMARKERS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK FACTORS; TENOFOVIR; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84945491814     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3775-9     Document Type: Article

References (39)

1. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology. 1986;6:167–172.
2. Hui CK, Leung N, Shek TW, et al. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007;46:690–698.
3. Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727–2734. doi:10.1007/s10620-010-1179-4.
4. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527.
5. Kuo L-F, Lee C-M, Hung C-H, et al. High risk of hepatitis B virus reactivation in nucleos(t)e analogue-induced hepatitis B e antigen seroconverters older than 40 years. Dig Dis Sci. 2014;59:2580–2587.
6. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003;37:748–755.
7. Poynard T, Hou J-H, Chutaputti A, Manns M, Naoumov N. Sustained durability of HBeAg seroconversion in chronic hepatitis B patients after treatment with telbivudine. J Hepatol. 2008;48:S268.
8. Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–806.
9. Jo K, Dodge JL, Wadley A, Wakil AE, Baron JL, Cooper S. HBeAg seroconversion is lower in Asian versus non-Asian patients during treatment of chronic hepatitis B with tenofovir or entecavir. Hepatology. 2013;58:669A.
10. Lee CM, Ong G-Y, Lin S-N, et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37:669–674.
11. Wang L, Liu F, Li X-Y, Wang J-B, Zhang Z-H, Wang Y-Z. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat. 2010;17:298–304.
12. Song BC, Cui XJ, Cho YK, et al. New scoring system for predicting relapse after lamivudine-induced hepatitis B e-antigen loss in chronic hepatitis B patients. Hepatol Res. 2009;39:1064–1071.
13. Fung J, Lai CL, Tanaka Y, et al. The duration of lamivudine therapy for chronic hepatitis B: cessation versus continuation of treatment after HBeAg seroconversion. Am J Gastroenterol. 2009;104:1940–1946.
14. Jin YJ, Kim KM, Yoo DJ, et al. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J. 2012;9:239.
15. Chien R-N, Yeh C-T, Tsai S-L, Chu C-M, Liaw Y-F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003;38:1267–1273.
16. Byun KS, Kwon OS, Kim JH, et al. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. J Gastroenterol Hepatol. 2005;20:1838–1842.
17. Kuo YH, Chen CH, Wang JH, et al. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75–81.
18. Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415–421.
19. Reijnders JGP, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2010;139:491–498.
20. Chaung KT, Ha NB, Trinh HN, et al. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastrol. 2012;46:865–870.
21. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
22. Ahn J, Lee HM, Lim J, et al. Entecavir safety and effectiveness in a natural cohort of chronic hepatitis B patients in the United States. The ENUMERATE study. Hepatology. 2014;60:1100A.
23. Lok ASF, McMahon B. Chronic hepatitis B. Hepatology. 2007;45:507–539.
24. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
25. Liaw YF, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561.
26. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10.
27. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437–1444.
28. Ridruejo E, Marciano S, Galdane O, et al. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat. 2014;21:590–596.
29. Song MJ, Song DS, Kim HY, et al. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol. 2012;18:6277–6283.
30. Publicover J, Goodsell A, Nishimura S, et al. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest. 2011;121:1154–1162.
31. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531.
32. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537–1547.
33. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.
34. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
35. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.
36. Wu CY, Lin JT, Ho HJ, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147:143–151.
37. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.
38. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) study group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.
39. Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62:760–765.